Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies.
Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, Faergeman O. Gerdes C, et al. Among authors: faergeman o. Circulation. 1997 Aug 5;96(3):733-40. doi: 10.1161/01.cir.96.3.733. Circulation. 1997. PMID: 9264476
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Olsson AG, Lindahl C, Holme I, Fayyad R, Faergeman O, Kastelein JJ, Tikkanen MJ, Larsen ML, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Olsson AG, et al. Among authors: faergeman o. Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):262-9. doi: 10.1177/1741826710389391. Epub 2011 Feb 8. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 21450674 Clinical Trial.
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Holme I, et al. Among authors: faergeman o. Ann Med. 2008;40(6):456-64. doi: 10.1080/07853890801964955. Ann Med. 2008. PMID: 19160529 Clinical Trial.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).
Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Pedersen TR, et al. Among authors: faergeman o. Circulation. 1998 Apr 21;97(15):1453-60. doi: 10.1161/01.cir.97.15.1453. Circulation. 1998. PMID: 9576425 Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: faergeman o. Int J Cardiol. 2013 Oct 9;168(4):3846-52. doi: 10.1016/j.ijcard.2013.06.024. Epub 2013 Aug 31. Int J Cardiol. 2013. PMID: 24001698 Clinical Trial.
Genes and cardiovascular risk.
Faergeman O. Faergeman O. Eur Heart J. 2013 Apr;34(13):949-50. doi: 10.1093/eurheartj/ehs439. Epub 2012 Dec 19. Eur Heart J. 2013. PMID: 23257949 No abstract available.
229 results